Autoantibodies against GFAP may represent a new and early serum marker of high diabetes ... (1:150), 3.5, 5, 6, 8, 10 and 20 weeks old, respectively; lane 8, 1:1,000 IgG GFAP antibody. B-and T ...

Type 1 diabetes is an autoimmune disease where beta cells, a hormone located in the pancreas that creates insulin, are destroyed, Busui says. This destruction may happen quickly or over some time ...

For type 1 diabetes, immunotherapy approaches show promise for delaying beta cell destruction when administered early in diagnosis. Researchers are also exploring beta cell transplantation ...

For Type 1 diabetes, immunotherapy approaches aim to prevent or reverse the autoimmune destruction of beta cells, while cell replacement therapies seek to restore insulin production through ...

What Is Type 1 Diabetes? Type 1 diabetes is a condition in which your immune system destroys insulin-making cells (beta cells) in your pancreas. That means your body can't make enough insulin or ...

Investigators in Australia have reactivated pancreatic stem cells from a donor with type 1 diabetes (T1D ... islet damage and significant destruction of beta cells. Therefore, the results of ...

“Both adult and childhood-onset type 1 diabetes are due to autoimmune destruction of cells in the pancreas, known as beta cells, that produce insulin,” says Rita R. Kalyani, MD, MHS, an ...

While its exact cause is not clear, Type 1 diabetes is believed to be impacted by an autoimmune reaction, states the CDC. This leads to the destruction of beta cells. If you have Type 1 diabetes ...

Researchers have uncovered a new way to slow or even prevent the destruction of these ... same mechanism could help protect beta cells in people with type 1 diabetes. Early lab tests using human ...

They also found that verapamil promotes IGF-1 signaling in pancreatic beta cells. Type 1 diabetes is an autoimmune disease that causes loss of the pancreatic beta cells that produce insulin. To ...

A Janus kinase (JAK) inhibitor helped preserve beta-cell function in people with recent-onset type 1 diabetes, the phase II BANDIT trial found. Meeting the study's primary endpoint, daily ...